After a busy 2016 spent acquiring other companies, Stryker Corp. is back in action. The company just announced its first deal of 2017.
Last year we predicted that, after a busy 2016, Stryker Corporation (NYSE: SYK), the Michigan-based medical device giant, would have a quiet 2017 as it integrated its new product lines.[...]
Mergers and acquisitions in the Laboratories, MRI and Dialysis sector increased nearly 30% through late June, compared with the same time last year. Fourteen acquirers inked 22 acquisitions, and most of[...]
Cross Country Healthcare, Inc. (NASDAQ: CCRN) hasn't announced an acquisition in more than a year. The company posted some rather soft numbers in Q1:17, owing to the slow pace of ramping[...]
The rehabilitation has historically been the smallest of all the healthcare sectors, typically accounting for the fewest number of deals and lowest dollar volume. Despite an abnormal 27 transactions announced[...]
PerkinElmer buys EUROIMMUN Medical Laboratory Diagnotics AG for $1.3 billion, after selling its medical imaging business back in December.
Health Care M&A Weekly Deals, The Week Ending June 16, 2017
Cross Country boosted its growth potential by acquiring Advantage RN, an independent nurse staffing agency.
The rehabilitation has historically been the smallest of all the healthcare sectors, typically accounting for the fewest number of deals and lowest dollar volume. Despite an abnormal 27 transactions announced in 2008, the sector generally saw between 10 and 20 deals a year, and minimal spending as well, (see chart below).
Drug companies and managed care organizations are working to keep prices from rising precipitously. Then there’s Pfizer.
Invitae, one of the fastest growing genetic information companies in the United States, is bolstering its product line with eHealth acquisitions.
It’s been a slow year for pharmaceutical M&A in the United States. But a group of Chinese investors has arrived to acquire SciClone, a specialty drug company.
Health care investors are moving out of sectors that could be hit with federal funding cuts, or become vilified in the media.
Contract research organizations (CROs) are hot targets this year. The heavy demand by pharma and biotech companies is attracting large private equity buyers.